Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLyell Immunopharma Inc

Lyell Immunopharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
15.0 USD -0.43 ( 2.79%)
Last update at 2026-11-05T21:00:00Z
VOLUME
657159
Market Cap
706.18M

Momentum Score

…

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.69
Low
16.20
High
52 Week Price Range
1.32
Low
3.97
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies and associated manufacturing approaches to improve T-cell persistence and anti-tumor activity for oncology indications. Long-term growth may be driven by progression of clinical programs, validation of its T-cell engineering platform in durable responses, and successful scale-up of manufacturing and commercialization capabilities. Investors may find exposure to next-generation cellular immunotherapies appealing given challenges conventional approaches face in solid tumors.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
15.43
Dividend Yield
-
Revenue TTM
0.07M
Revenue Per Share
-
Gross Profit TTM
84.68M
Debt / Equity
0.10
ROE
-32.93%
Net Debt
-82.48M
ROCE
-25.59%
Diluted EPS TTM
-0.90

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -183.12M -250.22M -204.47M -129.38M
Net income -4.75M -285.50M -198.53M -121.26M
Selling general administrative 117.31M 89.06M 46.88M 39.15M
Gross profit 84.68M 10.65M 7.76M 0.66M
Reconciled depreciation 18.02M 13.62M 4.29M 1.26M
Ebit -183.12M -214.78M -211.94M -102.09M
Ebitda -165.10M -164.71M -207.64M -100.83M
Depreciation and amortization 18.02M 50.07M 4.29M 1.26M
Non operating income net other - -36.61M - -
Operating income -183.12M -214.78M -211.94M -102.09M
Other operating expenses 276.50M 225.43M 219.69M 102.75M
Interest expense - 1.17M 5.94M 0.00M
Interest income 7.05M 1.17M 5.94M 8.12M
Net interest income 7.05M 1.17M 5.94M 8.12M
Income tax expense -178.36M 35.28M -5.94M -8.12M
Total revenue 84.68M 10.65M 7.76M 0.66M
Total operating expenses 276.50M 225.43M 219.69M 102.75M
Total other income expense net -178.36M -35.44M 7.46M -27.29M
Net income from continuing ops -183.12M -250.22M -204.47M -129.38M
Net income applicable to common shares -183.12M -250.22M -208.05M -130.52M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 750.03M 937.56M 1127.41M 908.28M 555.63M
Other current assets 8.46M 11.14M 11.49M 4.93M 4.21M
Total liab 95.08M 104.31M 197.62M 189.84M 147.58M
Total stockholder equity 654.95M 833.25M 929.79M 718.44M 408.06M
Other current liab 3.07M 6.71M 37.37M 30.18M 14.35M
Common stock 0.03M 0.03M 0.02M 0.00M 0.00M
Capital stock 0.03M 0.03M 0.02M 1010.97M 519.16M
Retained earnings -1002.11M -767.48M -584.36M -334.14M -129.67M
Other liab - 4.11M 84.23M 89.60M 98.41M
Other assets - 4.96M 3.95M 3.23M 2.68M
Cash 145.65M 123.55M 293.83M 140.41M 96.67M
Total current liabilities 34.52M 37.03M 46.74M 49.28M 22.05M
Current deferred revenue 20.36M 21.87M 4.99M 6.09M 4.51M
Net debt -82.48M -55.85M -226.01M -85.83M -69.20M
Short term debt 6.27M 4.53M 1.17M 3.62M 0.34M
Short long term debt total 63.17M 67.70M 67.82M 54.57M 27.47M
Other stockholder equity 1657.13M 1608.31M 388.34M 41.36M 18.11M
Property plant equipment - 166.26M 120.10M 124.06M 43.70M
Total current assets 554.69M 651.29M 626.29M 617.55M 440.26M
Long term investments 48.51M 115.04M 330.53M 163.44M 68.98M
Net tangible assets - 833.25M 929.79M -292.53M -111.11M
Short term investments 400.58M 516.60M 320.97M 472.21M 339.38M
Accounts payable 4.82M 3.92M 3.21M 9.40M 2.84M
Accumulated other comprehensive income -0.09M -7.60M -1.62M 0.26M 0.45M
Common stock total equity - - 0.02M 0.00M 0.00M
Retained earnings total equity - - -584.36M - -
Non currrent assets other 4.52M 4.96M 3.95M 3.23M 2.68M
Non current assets total 195.34M 286.27M 501.12M 290.73M 115.37M
Capital lease obligations 63.17M 67.70M 67.82M 50.96M 27.12M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -11.54M -56.07M -222.03M -406.39M
Change to liabilities -83.99M 8.31M -8.03M 104.63M
Total cashflows from investing activities -11.54M -121.57M -273.52M -422.43M
Total cash from financing activities 10.63M 401.24M 476.79M 351.16M
Change to operating activities 1.97M 14.43M 7.70M 6.18M
Net income -183.12M -250.22M -204.47M -129.38M
Change in cash -170.46M 153.42M 42.40M -31.80M
Begin period cash flow 294.29M 140.87M 98.47M 130.28M
End period cash flow 123.83M 294.29M 140.87M 98.47M
Total cash from operating activities -169.56M -126.25M -160.87M 39.47M
Issuance of capital stock 0.00M 391.80M 492.47M 351.34M
Depreciation 18.02M 13.62M 4.29M 1.26M
Sale purchase of stock 0.00M 401.24M -16.05M -0.18M
Other cashflows from financing activities 1.06M 9.44M 492.84M 351.34M
Change to netincome 77.56M 100.11M 39.64M 56.79M
Capital expenditures 24.28M 65.50M 51.48M 16.05M
Cash flows other operating - 0.02M - -
Cash and cash equivalents changes - 153.42M - -
Change in working capital -82.02M 4.01M -0.34M 110.81M
Stock based compensation 81.92M 62.20M 33.26M 15.73M
Other non cash items -6.68M 4.62M 11.99M 42.57M
Free cash flow -193.83M -191.75M -212.35M 23.43M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LYEL
Lyell Immunopharma Inc		 -0.43
2.79%		 15.00 - - 5883.30 1.17 2167.49 -1.24
NVO
Novo Nordisk A/S		 -1.88
4.46%		 40.30 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -6.54
1.19%		 542.50 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -27.77
2.98%		 902.90 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

201 Haskins Way, South San Francisco, CA, United States, 94080

650 695 0677

https://lyell.com

224

Name Title Year Born
Dr. Richard D. Klausner M.D. Founder & Exec. Chairman 1952
Ms. Elizabeth Homans CEO & Director 1966
Mr. Charles W. Newton Chief Financial Officer 1971
Mr. Stephen J. Hill Chief Operating Officer 1970
Prof. Stanley R. Riddell M.D. Founder & Scientific Advisor NA
Dr. Crystal L. Mackall M.D. Founder & Scientific Advisor NA
Nellie Dillery Director of Accounting NA
Mr. Richard Goold Ph.D. Chief Information Officer 1960
Dr. Gary Lee Ph.D. Chief Scientific Officer 1977
Ellen Rose VP of Communications & Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DHT-U
CAD 13.53
+16.44%
LIF
CAD 22.04
+8.62%
TOI
CAD 103.80
+7.09%
CRON
CAD 5.26
+6.69%
CIA
CAD 2.04
+6.25%
ITH
CAD 1.61
-34.02%
IFOS
CAD 1.65
-22.90%
TNZ
CAD 49.70
-19.58%
KEEL
CAD 2.36
-19.45%
GIL
CAD 49.36
-18.33%

Equity Sectors*

  • Basic Materials

    -2.18%

  • Communication Services

    +0.95%

  • Consumer Cyclical

    -2.25%

  • Consumer Defensive

    -0.68%

  • Energy

    -2.93%

  • Financial Services

    -2.26%

  • Healthcare

    -0.46%

  • Industrials

    -3.70%

  • Real Estate

    -0.06%

  • Technology

    -3.32%

  • Utilities

    -0.50%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…